Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECHOES-AF Pilot
ACTRN12623000949684Phase 2Withdrawn
- Sponsor
- The George Institute for Global Health
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabigatran, rivaroxaban, apixaban and edoxaban in Atrial fibrillation (AFib), atrial flutter (AFL), ischemic stroke and 1 more (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: All-cause mortality. Planned start Jul 2025; status: withdrawn.
02
Drugs
dabigatranrivaroxabanapixabanedoxaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ACTRN12623000949684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000949684.